Summary
Aging and Alzheimer’s disease (AD), a major age-related disorder, are both characterized by inflammatory changes in the cerebrospinal fluid (CSF). The origin and the mechanisms underlying these inflammatory changes, however, remain poorly understood. Here, we report that aging elicits inflammatory changes in the CSF that become accentuated uniquely in AD compared to other inflammatory and neurodegenerative disorders. We show that the choroid plexus (ChP), which produces CSF, gains a pro-inflammatory profile, exhibits perturbed metabolism and contributes to the CSF changes observed in AD. We then use MRI imaging to establish a correlation between cognitive decline and increased volume of significantly remodelled ChP in patients with AD, and provide clinical relevance to the identified ChP pathology. These findings collectively suggest that ChP, unable to resolve inflammatory insults efficiently over the lifetime, participates in the inflammation and the pathogenesis of AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the European Regional Development Funds No. CZ.02.1.01/0.0/0.0/16_019/0000868 ENOCH grant (S.B., J.D., G.F., J.F., M.H., J.H., S.K. and G.B.S.), Research Infrastructure RECETOX RI grant (No LM2018121) financed by the Ministry of Education, Youth and Sports, and Operational Programme Research, Development and Innovation - CZ.02.1.01/0.0/0.0/17_043/0009632 CETOCOEN EXCELLENCE project, and the HORIZON 2020 No. 857560 (J.D., G.B.S. and Z.S.), the Czech Ministry of Health grants NV 18-04-00346 (Z.N.), NV 18-04-00455 and 00064203 (J.H.), NV19-08-00472 (Z.S. and K.S.), the No. CZ.02.1.01/0.0/0.0/16_026/0008451 INBIO grant (J.D.), NIH grant P30 AGO62429 (R.A.R.), the Barrow Neurological Foundation and the Fein Foundation (R.B.), the research infrastructure LM2018121 RECETOX grant (Z.S.), the Grant Agency of the Masaryk University No. MUNI/G/1131/2017 GAMU (Z.S.) and MUNI/A/1615/2020 (S.K.) grants, the National Cancer Institute of the NIH grant No. P30CA033572 (P.P.), the NIA U01 grant U01AG061357 (E.B.D. and N.T.S.) and the Institutional Support of Excellence 2. LF UK grant 6990332 (J.H.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB/ethical approvals were obtaine from: Czech Brain Aging Study, St. Anne's University Hospital, Brno, and Motol Hospital, Prague, Barrow Neurological Institute, Phoenix, Alzheimer's Disease Neuroimaging Initiative, Buenos Aires, Argentina, Shiley-Marcos Alzheimer's Disease Research Centre, University of California San Diego, Imperial College Parkinson's UK Brain Bank
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data are available upon request once the manuscipt is published.
